{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 44,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "context",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The slide uses clinical data to establish the biological rationale for the therapeutic approach.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/7",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.71,
        "x": 0.145,
        "y": 0.935
      },
      "kind": "disclaimer",
      "text": "*FARS: Friedreich’s ataxia rating scale, measures disease progression with a higher score indicating a greater level of disability; **FXN levels measured in peripheral blood mononuclear cells (PBMCs). FXN levels demonstrated to be equivalent in PBMCs, buccal cells, and whole blood.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f7fa433-a149-454e-a107-1763039528b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.31,
        "x": 0.65,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "Adapted from C. Rummey et al. EClinicalMedicine. 2020 18:100213",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c2748e0-d803-425f-8f22-49b4e2143d29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.289,
        "x": 0.178,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "Adapted from H.L.Plasterer et al. PLoS ONE 2013 8(5):e63958",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d88d50f2-092e-4b8d-bfe5-b20a476b40e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.43,
        "x": 0.037,
        "y": 0.315
      },
      "kind": "table",
      "text": "Median Age of Onset and Rate of Disease Progression in Relation to FXN Levels",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "288d228a-0364-4197-8f6b-c6c79329b57b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.43,
        "x": 0.528,
        "y": 0.315
      },
      "kind": "table",
      "text": "Median Age of Onset Predicts Time to Loss of Ambulation",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a123aaa0-ad68-4c00-94ee-ea7b42f96765",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.925,
        "x": 0.037,
        "y": 0.145
      },
      "kind": "title",
      "text": "Lower FXN levels are associated with earlier onset of disease, faster rate of disease progression, and shorter time to loss of ambulation",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c2b49b6-de29-4615-9838-1bee59ad6d3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.817,
        "x": 0.037,
        "y": 0.075
      },
      "kind": "title",
      "text": "FXN Levels Determine Disease Progression in FA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db27c64b-8d39-4f62-b253-185dcfd2b577",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "3ff86409-4f92-49c1-b993-6cc96019c006",
      "evidence": "The slide explicitly links FXN levels to disease progression metrics.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 7,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "59b04e7b-c635-4d71-b3eb-06c09a7648ae",
      "evidence": "Pages 6-7 discuss the disease progression and impact",
      "position": 0,
      "objective": "What is the cost of not treating FA?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}